# OnCo record relapsed-refractory-hodgkin-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "relapsed-refractory-hodgkin-lymphoma" ;
  schema:name "Relapsed and refractory classical Hodgkin lymphoma"@en ;
  schema:alternateName "Relapsed Hodgkin lymphoma"@en, "Refractory Hodgkin lymphoma"@en, "R/R cHL"@en, "Hodgkin lymphoma after first-line failure"@en ;
  schema:description "Relapsed or refractory classical Hodgkin lymphoma is Hodgkin lymphoma that comes back or does not respond after first-line chemotherapy. The standard path is salvage chemotherapy, often with brentuximab vedotin or a PD-1 antibody, then high-dose chemotherapy with an autologous stem cell transplant; for those who relapse again, nivolumab and pembrolizumab give lasting control in many."@en ;
  schema:url <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(15)60165-9>, <https://doi.org/10.1016/S1470-2045(21)00005-X>, <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  onco:tag "subtype-page", "haematologic" ;
  onco:related <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/> ;
  onco:targets <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/penpulimab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/everolimus/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/reed-sternberg-cell/>, <https://onco.cc/terms/late-effects/> ;
  onco:trials <https://onco.cc/trials/aethera/>, <https://onco.cc/trials/keynote-204/>, <https://onco.cc/trials/checkmate-205/>, <https://onco.cc/trials/nct04268706/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/>, <https://onco.cc/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/>, <https://onco.cc/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/> ;
  onco:pipeline <https://onco.cc/trials/nct04268706/>, <https://onco.cc/ideas/idea-cd30-car-t-hodgkin/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/> ;
  onco:standardOfCare <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/trials/aethera/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-204/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/checkmate-205/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/penpulimab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/trials/nct04268706/>, <https://onco.cc/ideas/idea-cd30-car-t-hodgkin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/imrt-igrt/> .